Astellas Pharma (OTCMKTS:ALPMY) Sees Strong Trading Volume – Still a Buy?
by Amy Steele · The Cerbat GemShares of Astellas Pharma Inc. (OTCMKTS:ALPMY – Get Free Report) saw an uptick in trading volume on Monday . 133,468 shares were traded during mid-day trading, a decline of 15% from the previous session’s volume of 157,048 shares.The stock last traded at $15.07 and had previously closed at $15.18.
Analysts Set New Price Targets
Separately, Zacks Research downgraded shares of Astellas Pharma from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, July 22nd. One investment analyst has rated the stock with a Strong Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy”.
View Our Latest Report on Astellas Pharma
Astellas Pharma Trading Up 0.9%
The stock has a market capitalization of $27.78 billion, a price-to-earnings ratio of 11.68 and a beta of 0.08. The company has a current ratio of 1.20, a quick ratio of 0.93 and a debt-to-equity ratio of 0.16. The company has a fifty day moving average of $14.44 and a two-hundred day moving average of $14.53.
Astellas Pharma Company Profile
Astellas Pharma Inc is a Japan-based pharmaceutical company that discovers, develops and commercializes prescription medicines for serious and unmet medical needs. Its research and commercial activities focus on areas including oncology, urology, immunology, neuromuscular diseases, ophthalmology and other specialty conditions.
The company’s portfolio includes treatments such as XTANDI for certain prostate cancers, XOSPATA for acute myeloid leukemia, MYRBETRIQ for overactive bladder and VEOZAH for menopausal hot flashes.